Xenon pharmaceuticals inc. (XENE)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Revenue (note 13):

6,829

-

-

-

-

-

-

-

Collaboration revenue (note 12)

-

-

311

-

-

-

-

-

Collaboration revenue

-

-

-

1,767

15,573

28,366

27,352

-

Collaboration revenue (note 10)

-

-

-

-

-

-

-

14,300

Royalties

-

-

-

36

4

4

4

8

Revenues

-

-

-

1,803

15,577

28,370

27,356

14,308

Operating expenses:
Research and development

38,845

23,634

25,573

19,828

15,152

11,768

12,303

10,455

General and administrative

10,803

8,406

7,313

6,792

9,786

5,496

5,341

7,006

Buy-out of future milestones and royalties (note 14c)

-

6,000

-

-

-

-

-

-

Total operating expenses

49,648

38,040

32,886

26,620

24,938

17,264

17,644

17,461

Loss from operations

-42,819

-38,040

-32,575

-24,817

-9,361

11,106

9,712

-3,153

Other income (expense):
Interest income

2,353

1,216

477

504

542

568

338

144

Interest expense

1,434

1,394

-

-

-

-

64

93

Foreign exchange gain (loss)

282

-701

1,394

1,316

-6,933

1,344

2,035

-169

Gain on termination of collaboration agreement (note 13c)

-

4,398

-

-

-

-

-

-

Loss before income taxes

-41,618

-34,521

-

-

-

-

-

-

Income tax recovery

-23

-24

-

-

-

-

-

-

Gain on write-off and disposal of assets

-

-

-

-

-

-

11

-1,030

Net loss and comprehensive loss

-41,595

-34,497

-30,704

-22,997

-15,752

13,018

12,032

-4,301

Net loss attributable to preferred shareholders

1,568

2,881

-

-

-

-

-

-

Net income attributable to participating securities

-

-

-

-

-

-

8,199

-

Net loss attributable to common shareholders

-40,027

-31,616

-30,704

-

-

-

3,833

-4,301

Net loss per common share (note 6):
Basic

-

-

-1.71

-1.48

-1.10

4.11

2.87

-3.24

Diluted

-

-

-1.72

-1.48

-1.10

3.28

1.91

-3.24

Basic and diluted

-1.54

-1.63

-

-

-

-

-

-

Weighted-average common shares outstanding (note 6):
Basic

-

-

17,985

15,493

14,281

3,165

1,337

1,327

Stock options

-

-

-

-

-

798

659

-

Subscription rights

-

-

-

-

-

-

12

-

Diluted

-

-

18,001

15,493

14,281

3,963

2,009

1,327

Foreign currency translation adjustment

-

-

-

-

-

-3,501

-1,236

-

Comprehensive income (loss)

-

-

-

-

-

9,517

10,796

-

Basic and diluted

25,939

19,425

-

-

-

-

-

-